Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Patrick Giugliano, M.D.

Co-Author

This page shows the publications co-authored by Robert Giugliano and Kazuma Oyama.
Connection Strength

0.821
  1. Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. Eur Heart J. 2021 12 14; 42(47):4821-4829.
    View in: PubMed
    Score: 0.244
  2. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021 05 01; 42(17):1698-1706.
    View in: PubMed
    Score: 0.234
  3. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021 01 26; 77(3):259-267.
    View in: PubMed
    Score: 0.226
  4. Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. Circulation. 2021 07 20; 144(3):249-251.
    View in: PubMed
    Score: 0.059
  5. Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects - A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial. Circ J. 2021 10 25; 85(11):2063-2070.
    View in: PubMed
    Score: 0.059
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.